Cafepharma Today

May 16 2025 - Novo CEO to depart as obesity drugmaker’s challenges rise
Novo CEO to depart as obesity drugmaker’s challenges rise
BioMarin expands enzyme expertise with $270M Inozyme buy
Amgen could owe Regeneron more than $400M after defeat in cholesterol drug antitrust suit
Eli Lilly collaborates with Rznomics on hearing loss treatment in $1.3 billion pact
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

Epizyme: The Promise Of Personalized Cancer Therapy
Seeking Alpha
Monday, September 16, 2013 - 11:03am
tags:
Epizyme, personalized medicine, GSK, cancer, Eisai, epigenetics, Celgene
FDA Grants Soligenix Orphan Drug Designation for SGX94 for Treatment of Acute Radiation Syndrome
Yahoo
Monday, September 16, 2013 - 11:01am
tags:
FDA, orphan drugs, SGX94, Soligenix, acute radiation syndrome
OncoSec Medical Announces $12 Million Public Offering
Yahoo
Monday, September 16, 2013 - 10:57am
tags:
stock offering, OncoSec
Dendreon's Provenge: A Major Focus At The European Cancer Congress 2013
Seeking Alpha
Monday, September 16, 2013 - 10:56am
tags:
Dendreon, Provenge, Europe, prostate cancer
Advertising Starts On Arena's Belviq
Seeking Alpha
Monday, September 16, 2013 - 10:15am
tags:
drug ads, Arena Pharmaceuticals, Belviq, obesity, Eisai
Breakthrough status for GSK and Genmab leukemia drug
Pharma Times, UK
Monday, September 16, 2013 - 10:14am
tags:
GSK, Genmab, breakthrough therapies, Arzerra, chronic lymphocytic leukemia, FDA
Amarin - Still Not Worried By A Generic Lovaza And An Update On Vascepa
Seeking Alpha
Monday, September 16, 2013 - 10:12am
tags:
Amarin, generics, Vascepa, Lovaza
NanoViricides Reports It Has Successfully Improved HIVCide Drug Candidate in Cell Culture Studies
Yahoo
Monday, September 16, 2013 - 10:11am
tags:
NanoViricides, HIVCide, HIV
Wall Street Sees Big Biotech Making Tens of Billions in Two Critical Areas
Yahoo/Wall St 24-7
Monday, September 16, 2013 - 10:09am
tags:
biotech, Th2 immune pathway, MS, multiple sclerosis, Biogen Idec, Regeneron, Sanofi, GSK
Bristol-Myers Squibb: Another Brick In The Wall
Seeking Alpha
Monday, September 16, 2013 - 10:07am
tags:
Bristol-Myers Squibb, Yervoy, prostate cancer
Odd Move By Sanofi On Diabetes Drug Application
Yahoo/YCharts
Monday, September 16, 2013 - 10:06am
tags:
diabetes, Sanofi, lixisenatide
Drug authority nod to buoy Sun Pharma
Hindu Business Line, India
Sunday, September 15, 2013 - 12:31pm
tags:
Sun Pharma, Lansoprazole, ulcers
3 Drug Classes That May Become Obsolete Within 3 Years
Motley Fool
Sunday, September 15, 2013 - 12:26pm
tags:
interferon, hepatitis C, type 2 diabetes, dialysis
Is This Diabetes Drug Stock in Jeopardy?
Motley Fool
Sunday, September 15, 2013 - 12:25pm
tags:
Novo Nordisk, Victoza, diabetes, type 2 diabetes
Key Problems Behind Teva's Lackluster 2013
Motley Fool
Sunday, September 15, 2013 - 12:19pm
tags:
Teva Pharmaceuticals
Sun Pharma gets USFDA nod for duodenal ulcer capsules
Hindu Business Line, India
Saturday, September 14, 2013 - 11:15am
tags:
Sun Pharma, Prevacid, generics
ViroPharma Skyrockets on Buyout Rumors
equities.com
Saturday, September 14, 2013 - 11:13am
tags:
ViroPharma, M&A
Making Sense of the Sunshine Act
Pharmexec
Saturday, September 14, 2013 - 11:08am
tags:
Physician Payment Sunshine Act
Should A Generic Lovaza Worry Amarin Longs?
Seeking Alpha
Saturday, September 14, 2013 - 11:07am
tags:
Amarin, Lovaza, generics
Raptor's Procysbi approved for rare disease in EU
PharmaTimes
Saturday, September 14, 2013 - 11:05am
tags:
Raptor Pharmaceuticals, procysbi, nephropathic cystinosis

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

Alzheimer's Update: Infectious Agents and Gamma-Secretase Too
In the Pipeline
Obesity Without Metabolic Dysfunction?
In the Pipeline
New Cell Therapy For Resistant Hodgkins Patients
In the Pipeline
Escape From the Lysosome
In the Pipeline
Heavy Water in Your NMR Experiments, And Elsewhere
In the Pipeline
GIPR: Agonists and Antagonists Do the Same Thing, But How
In the Pipeline
Mutant Proteins Classified
In the Pipeline
The Continuing Crisis, Part XIV: The Trumpist Worldview
In the Pipeline
Whole Lotta Snakin' Going On
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.